Detalhe da pesquisa
1.
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
Ann Oncol
; 33(11): 1186-1199, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35988656